Pipeline — registered trials by phase
Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
— · Breast Neoplasms, Carcinoma, Ductal, Breast, Receptors, Estrogen (for ER-positive Requirement) · Recruiting · est. 2032-05-15
LAMBDA 002 (Lung Registry) Study
— · Lung Transplant Rejection · Active Not Recruiting · est. 2026-08
Signatera-Guided De-escalation of Adjuvant Therapy in Resectable Stage II-IVa Gastric/Gastric-Esophageal Cancer
— · Gastric-Esophageal Cancer · Not Yet Recruiting · est. 2028-09
Clinical Use of Parental Support To Detect Single Gene Mutations
— · Single Gene Disorders · Completed · est. 2013-06
Sample Collection for Ongoing Research and Product Evaluation Study - Non-muscle Invasive Bladder Cancer (SCORE-NMIBC)
— · Non-Muscle Invasive Bladder Cancer, NMIBC, High-risk Non-Muscle Invasive Bladder Cancer · Recruiting · est. 2032-07
Clinical Utility of the Addition of a SNP-based NIPT Zygosity Determination in Twin Pregnancy Management.
— · Twin to Twin Transfusion Syndrome, Pregnancy Complications, Multiple Gestation; Maternal Care · Completed · est. 2023-05-15
Prospera Test Evaluation in Cardiac Transplant (ProTECT)
— · Heart Transplant Rejection · Active Not Recruiting · est. 2026-10-31
Sample Collection for Ongoing Research and Product Evaluation Study
— · Breast Cancer, Lung Cancer, Muscle Invasive Bladder Cancer · Recruiting · est. 2035-01
The PROspera Kidney Transplant ACTIVE Rejection Assessment Registry (ProActive)
— · Kidney Transplant Rejection · Active Not Recruiting · est. 2026-10-01
Evaluation of the Natera Colorectal Cancer Screening Test in an Average Risk Population (FIND-CRC)
— · Colo-rectal Cancer · Recruiting · est. 2027-07-10
SNP-based Microdeletion and Aneuploidy RegisTry (SMART)
— · 22q11 Deletion Syndrome, DiGeorge Syndrome, Trisomy 21 · Completed · est. 2020-06
BESPOKE Study of ctDNA Guided Immunotherapy
— · Colorectal Cancer, Melanoma, Non-small Cell Lung Cancer · Completed · est. 2023-12-31
Multiple Gestation Study
— · Trisomy 13, Trisomy 18, Trisomy 21 · Completed · est. 2019-03
Collection of Maternal Blood Samples for Development of Non-invasive Prenatal Diagnostic Testing
— · Pregnancy Following IVF With PGS/PGD · Completed · est. 2012-05
Study for the Prediction of Active Rejection in Organs Using Donor-derived Cell-free DNA Detection
— · Transplant Rejection, Allograft Rejection, Complications · Completed · est. 2024-08-23
Concurrent Single Gene and 24 Chromosome Aneuploidy Preimplantation Genetic Diagnosis (PGD)
— · Any Single Gene Disorder (Cystic Fibrosis, Tay-Sachs) · Completed · est. 2014-03
Immunosuppression Optimization Using The Prospera Assay In Kidney Transplant Recipients (IMPAKT)
— · Kidney Transplant, Immunosuppresion · Not Yet Recruiting · est. 2027-12
Signatera Assessment in Early-Stage Endometrial Cancer
— · Endometrial Cancer · Not Yet Recruiting · est. 2034-10
Development of Non-invasive Prenatal Screening Test for Microdeletions Based on Fetal DNA Isolated From Maternal Blood
— · Trisomy 21, Trisomy 18, Trisomy 13 · Completed · est. 2020-10
Sample Collection for Ongoing Research and Product Evaluation Study - Non-Hodgkin Lymphoma (SCORE-NHL)
— · Non-Hodgkin Lymphoma, T-Cell Lymphoma, Diffuse Large B-Cell Lymphoma · Recruiting · est. 2032-04
Non-invasive Prenatal Diagnostic Validation Study
— · Chromosome 13 Aneuploidy, Chromosome 18 Aneuploidy, Chromosome 21 Aneuploidy · Completed · est. 2013-04
Development of Non-invasive Cell-free DNA to Supplant Invasive Biopsy in Heart Transplantation
— · Heart Transplant · Completed · est. 2024-10-02
EXpanding Prenatal Cell Free DNA Screening Across moNogenic Disorders (EXPAND)
— · Single Gene NIPT · Recruiting · est. 2027-04
Prospective Collection of Samples to Enable the Development of Natera Screening Assay for Early Cancer Detection
— · Colorectal Cancer Screening · Recruiting · est. 2025-07-31
A Comparative Effectiveness Study in Heart Transplant Patients of Rejection Surveillance With Cell-free DNA Versus Endomyocardial Biopsy
— · Heart Transplant Failure and Rejection · Active Not Recruiting · est. 2027-02
No registered trials in this stage.
No registered trials in this stage.
No registered trials in this stage.
No approved products listed under this sponsor in Drugs@FDA (partnered or subsidiary products may be listed elsewhere).
Source: ClinicalTrials.gov (trials where Natera is lead sponsor; 29 active or completed) and Drugs@FDA (0 approved products). Registry data can include older or partnered programs; the company's own pipeline page is the official list.
SEC filings — insider trading forms excluded
- SCHEDULE 13G/A2026-08-14SCHEDULE 13G/A
- S-82026-08-07Employee stock plan
- 10-Q2026-08-07Quarterly report
- 8-K2026-08-06Current report (material event)
- 8-K2026-07-06Current report (material event)
- 8-K/A2026-06-16Current report (amended)
- 8-K2026-06-16Current report (material event)
- 8-K2026-06-05Current report (material event)
- 10-Q2026-05-08Quarterly report
- 8-K2026-05-07Current report (material event)
- SCHEDULE 13G2026-04-30SCHEDULE 13G
- ARS2026-04-23Annual report to holders
- DEFA14A2026-04-23DEFA14A
- DEF 14A2026-04-23Proxy statement
- 8-K2026-04-01Current report (material event)
- SCHEDULE 13G/A2026-03-27SCHEDULE 13G/A
- S-82026-03-02Employee stock plan
- 10-K2026-02-27Annual report
- 8-K2026-02-26Current report (material event)
- SCHEDULE 13G/A2026-02-17SCHEDULE 13G/A
- SCHEDULE 13G/A2026-01-23SCHEDULE 13G/A
- 8-K2026-01-12Current report (material event)
- S-3ASR2025-12-10S-3ASR
- RW2025-12-10RW
- S-82025-12-05Employee stock plan
- S-32025-12-05Shelf registration
- 8-K2025-12-05Current report (material event)
- 10-Q2025-11-07Quarterly report
- 8-K2025-11-06Current report (material event)
- S-82025-10-21Employee stock plan
- SCHEDULE 13G/A2025-08-14SCHEDULE 13G/A
- 10-Q2025-08-08Quarterly report
- 8-K2025-08-07Current report (material event)
- SCHEDULE 13G/A2025-07-22SCHEDULE 13G/A
- 8-K2025-06-18Current report (material event)
- SCHEDULE 13G/A2025-05-14SCHEDULE 13G/A
- 10-Q2025-05-09Quarterly report
- 8-K2025-05-08Current report (material event)
- ARS2025-04-24Annual report to holders
- DEFA14A2025-04-24DEFA14A
Source: SEC EDGAR. Forms 3/4/5 and 144 (insider transactions) are intentionally left out.